LOS GATOS, CA / ACCESSWIRE / May 17, 2023 / Tenon Medical, Inc. ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders, today announced the Company will participate in The Benchmark Company Healthcare House Call Virtual 1x1 Investor Conference on Tuesday, May 23, 2023.
Steven Foster, Tenon Chief Executive Officer and President, and Steven Van Dick, Tenon Chief Financial Officer, will attend and will be available for virtual one-on-one and small group meetings.
For more information on the conference, please contact your conference representative. Meeting requests may also be emailed to This email address is being protected from spambots. You need JavaScript enabled to view it..
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, transfixing the SI joint along its longitudinal axis. With an entry that mimics SI joint injection, the surgical approach is direct to the joint and inferior to the wide and variable dorsal recess. The angle and trajectory of the Inferior-Posterior approach is designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Tenon is preparing a national launch of this system to address the greatly underserved market opportunity that exists in this space. For more information, please visit www.tenonmed.com.
The Tenon Medical logo and Tenon Medical, are registered trademarks of Tenon Medical, Inc. Catamaran is a trademark of Tenon Medical, Inc.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.15 |
Daily Change: | 0.27 14.41 |
Daily Volume: | 600,862 |
Market Cap: | US$6.750M |
October 30, 2024 October 17, 2024 September 19, 2024 September 17, 2024 September 12, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB